Research Study Background
Eli Lilly a new CDK4 & 6 inhibitor, Verzenio (abemaciclib) got US FDA approval on 17th September 2017 in combination with fulvestrant for women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) for advanced or metastatic breast cancer. Verzenio got marketing approval on the basis of MONARCH 2 Phase 3 Trial and MONARCH 1 Phase 1 Trial where abemaciclib in combination with fulvestrant demonstrated a greater than 16-month median progression-free survival (PFS) in patients who progressed on endocrine therapy. Eli Lilly and Company was hoping for success of Verzenio in Lung Cancer patient because abemaciclib was failed to improve overall survival in a Phase 3 study testing it in lung cancer patients with a mutation. FDA approval of Verzenio illustrates devotion to determining, evolving, and providing innovative, foundational medicines that offers a meaningful difference to patients with Breast Cancer.
Sentiment Analysis on Verzenio Drug Approval
Positive: Aliqopa approval was quoted as an Impressive breakthrough - "Thank goodness FDA approved a me too drug while not a single drug of this class has shown OS benefit in RCT" @vinayprasad82 on abemaciclib- MiteshBorad (HCP)
Neutral: Majority of healthcare practitioners and patients were either neutral or positive about the approval, efficacy and found sharing the information on social media platform- “The FDA approved Eli Lilly’s breast-cancer drug Verzenio!”- (Unidentified Individual)